| 90451-6 |
Herpes simplex virus 1 DNA |
PrThr |
Asp |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 1 DNA [Presence] in Aspirate by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90451-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV1 DNA Aspirate Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Aspirate; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 1; HSV; HSV1; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90452-4 |
Herpes simplex virus 1 DNA |
PrThr |
Respiratory system specimen.upper |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 1 DNA [Presence] in Upper respiratory specimen by NAA with probe detection |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90452-4 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV1 DNA Upper resp Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Breathing; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 1; HSV; HSV1; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lung; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QL; Qual; Qualitative; Random; Respiratory; RS; Screen; SDA; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification; Up; Upper resp |
2.77 |
2.65 |
|
|
|
|
|
|
|
|
|
|
Release 2.77: SYSTEM: Updated to standardize the representation of "Respiratory system specimen" in the System subhierarchy across LOINC; |
0 |
| 90453-2 |
Herpes simplex virus 2 DNA |
PrThr |
Asp |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 2 DNA [Presence] in Aspirate by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90453-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV2 DNA Aspirate Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Aspirate; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 2; Herpes simplex virus type II; HSV; HSV2; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90454-0 |
Herpes simplex virus 2 DNA |
PrThr |
Respiratory system specimen.upper |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 2 DNA [Presence] in Upper respiratory specimen by NAA with probe detection |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90454-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV2 DNA Upper resp Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Breathing; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 2; Herpes simplex virus type II; HSV; HSV2; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lung; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QL; Qual; Qualitative; Random; Respiratory; RS; Screen; SDA; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification; Up; Upper resp |
2.77 |
2.65 |
|
|
|
|
|
|
|
|
|
|
Release 2.77: SYSTEM: Updated to standardize the representation of "Respiratory system specimen" in the System subhierarchy across LOINC; |
0 |
| 90455-7 |
Influenza virus A & B RNA panel |
- |
Cornea/Conjunctiva |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Influenza virus types A and B panel - Cornea or Conjunctiva by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
90455-7 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
FLUAV + FLUBV Pnl Corn/Cnjt NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; A,B; Amplif; Amplification; Amplified; Avian influenza; Bird flu; Corn/Cnjt; Corneal; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV + FLUBV; FLUAV + FLUBV Pnl; FLUAV+FLUBV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 90456-5 |
Influenza virus A & B RNA panel |
- |
CSF |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Influenza virus types A and B panel - Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
90456-5 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
FLUAV + FLUBV Pnl CSF NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; A,B; Amplif; Amplification; Amplified; Avian influenza; Bird flu; Cerebral spinal fluid; Cerebrospinal Fl; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV + FLUBV; FLUAV + FLUBV Pnl; FLUAV+FLUBV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 90457-3 |
Influenza virus A & B RNA panel |
- |
Tiss |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Influenza virus types A and B panel - Tissue by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
90457-3 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
FLUAV + FLUBV Pnl Tiss NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; A,B; Amplif; Amplification; Amplified; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV + FLUBV; FLUAV + FLUBV Pnl; FLUAV+FLUBV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; SDA; Strand Displacement Amplification; Tissue; Tissue, unspecified; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 90458-1 |
Actinomyces sp |
Prid |
Asp |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Actinomyces sp identified in Aspirate by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90458-1 |
|
Organism specific culture |
|
|
Observation |
|
|
|
0 |
Actinomyces Aspirate Cult |
|
|
|
|
|
Actino; Aspirate; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Spec; species; spp |
2.79 |
2.65 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 90459-9 |
Yellow fever virus RNA |
PrThr |
Bld |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Yellow fever virus RNA [Presence] in Blood by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90459-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
YFV RNA Bld Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; American plague; Amplif; Amplification; Amplified; Blood; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood; yellow jack; YFV |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9046-4 |
Calcium intake |
Sub |
^Patient |
Pt |
Qn |
Measured |
|
ACTIVE |
Calcium intake Measured |
|
MIN |
DefinitionDescription |
|
|
mol |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9046-4 |
|
Measured |
|
|
|
|
|
|
0 |
Calcium intake Measured |
|
|
|
|
|
Ca; Cal; IO_INTAKE_SALTS+CALORIES; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance amount |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol |
|
|
|
0 |
| 90460-7 |
Hepatitis E virus RNA |
PrThr |
Ser/Plas |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Hepatitis E virus RNA [Presence] in Serum or Plasma by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90460-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HEV RNA SerPl Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Hep; Hep E; Hepatis; Hepatit; Hepatology; HEV; HEV RNA; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90461-5 |
Herpes simplex virus 1+2 Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Herpes simplex virus 1+2 IgG Ab [Presence] in Serum by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90461-5 |
|
IA |
|
|
Both |
|
|
|
0 |
HSV1+2 IgG Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type 1+2; Herpes simplex virus type I+II; HSV; HSV 1+2; HSV1; HSV1+2; i; IAA; ID; II; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90462-3 |
Zika virus RNA |
PrThr |
BldCo |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Zika virus RNA [Presence] in Cord blood by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90462-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
ZIKV RNA BldCo Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood - (umbilical) cord; Cord (umbilical) blood; Cord bld; Cord blood; DNA NUCLEIC ACID PROBE; DNA probe; Gyn; Gynecology; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; OB; ObGyn; Obstetrics; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; ZIKV; ZIKV RNA |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90463-1 |
Adenovirus DNA |
PrThr |
Respiratory system specimen.lower |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA [Presence] in Lower respiratory specimen by NAA with probe detection |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90463-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HAdV DNA Lower resp Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Adeno virus; Amplif; Amplification; Amplified; Breathing; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Low; Lower resp; Lung; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; Pulmonary; Pulmonology; QBR; QL; Qual; Qualitative; Random; Respiratory; RS; Screen; SDA; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.77 |
2.65 |
|
|
|
|
|
|
|
|
|
|
Release 2.77: SYSTEM: Updated to standardize the representation of "Respiratory system specimen" in the System subhierarchy across LOINC; |
0 |
| 90464-9 |
Herpes simplex virus 1+2 Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Herpes simplex virus 1+2 IgM Ab [Presence] in Serum by Immunoassay |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
90464-9 |
|
IA |
|
|
Both |
|
|
|
0 |
HSV1+2 IgM Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type 1+2; Herpes simplex virus type I+II; HSV; HSV 1+2; HSV1; HSV1+2; i; IAA; ID; II; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90465-6 |
3-(4-fluorobenzoyl)propionate |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
3-(4-fluorobenzoyl)propionate [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
90465-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
FBPA Ur Cfm-mCnc |
|
|
|
|
|
4 fluorobenzoyl propionic acid; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FBPA; GCMS; Haloperidol metabolite; III; LC/MS/MS; Level; Mass concentration; Point in time; Propanoic acid; Propioate; Propioic acid; Propionic acid; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 90466-4 |
3-(4-fluorobenzoyl)propionate |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
3-(4-fluorobenzoyl)propionate [Presence] in Urine by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
90466-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
FBPA Ur Ql Scn |
|
|
|
|
|
4 fluorobenzoyl propionic acid; DRUG/TOXICOLOGY; Drugs; FBPA; Haloperidol metabolite; III; Ordinal; Point in time; PR; Propanoic acid; Propioate; Propioic acid; Propionic acid; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90467-2 |
Hydroxyaripiprazole |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyaripiprazole [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
90467-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-aripiprazole Ur Cfm-mCnc |
|
|
|
|
|
Aripiprazole metabolite; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; OH-aripiprazole; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 90468-0 |
Hydroxyaripiprazole |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Hydroxyaripiprazole [Presence] in Urine by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
90468-0 |
|
Screen |
|
|
Both |
|
|
|
0 |
OH-aripiprazole Ur Ql Scn |
|
|
|
|
|
Aripiprazole metabolite; DRUG/TOXICOLOGY; Drugs; OH-aripiprazole; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90469-8 |
Norfluvoxamine |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Norfluvoxamine [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
90469-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Norfluvoxamine Ur Cfm-mCnc |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 9047-2 |
Calcium intake |
SRat |
^Patient |
1H |
Qn |
|
|
ACTIVE |
Calcium intake 1 hour |
|
MIN |
DefinitionDescription |
|
|
mol/h |
|
|
|
|
|
|
IO_IN_SALTS+CALS |
|
9047-2 |
|
|
|
|
|
|
|
|
0 |
Calcium intake 1h |
|
|
|
|
|
1 hour; 1.0Hr; 1HR; 60 min; 60 minutes; 60M; 60min; Ca; Cal; IO_INTAKE_SALTS+CALORIES; QNT; Quan; Quant; Quantitative; sRate; Substance Rate |
2.48 |
1.0i |
|
|
|
|
|
|
|
mol/h |
|
|
|
0 |
| 90470-6 |
Norfluvoxamine |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
Norfluvoxamine [Presence] in Urine by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
90470-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
Norfluvoxamine Ur Ql Scn |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90471-4 |
9-Hydroxyrisperidone |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
9-Hydroxyrisperidone [Presence] in Urine by Screen method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
90471-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
9OH-risperidone Ur Ql Scn |
|
|
|
|
|
9-Hydroxy risperidone; 9-Hydroxy-risperidone; 9-OH-Risperidone; 9OH-risperidone; DRUG/TOXICOLOGY; Drugs; Invega; Ordinal; Paliperidone; Point in time; PR; QL; Qual; Qualitative; Random; Risperidone metabolite; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.65 |
2.65 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 90472-2 |
Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.17.1, 1.17.2 |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
Minimum Data Set (MDS) - version 3.0 - Resident Assessment Instrument (RAI) version 1.17.1, 1.17.2 during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
90472-2 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; MDS; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.66 |
|
Convenience group |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.68: COMPONENT: Version 1.17.2 was added to the Component because this panel now represents both versions. |
0 |
| 90473-0 |
MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home comprehensive (NC) item set |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.17.1, 1.17.2 - Nursing home comprehensive (NC) item set during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
90473-0 |
|
CMS Assessment |
|
|
Order |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.66 |
|
Panel |
|
|
|
|
|
|
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Release 2.68: DefinitionDescription: Added missing Term Description; COMPONENT: Version 1.17.2 was added to the Component because this panel now represents both versions.; Release 2.67: DefinitionDescription: Added missing Term Description |
0 |
